Intelligence Feed event · Equity · 2026-09-21

    Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen

    Question

    Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen

    Direct answer

    Ionis Pharmaceuticals has faced substantial equity re-rating in 2026, falling more than 40% on the back of late-stage clinical trial disappointments and recurring operating losses. The pipeline setbacks have centered on lead programs pelacarsen and eplontersen, impacting near-term commercialization milestones. Despite the share price decline, sell-side consensus maintains an average target of $83.82, reflecting residual valuation attributed to Ionis's broad antisense oligonucleotide technology library and established partnerships with AstraZeneca, Roche, and Biogen.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/ionis-plunges-over-40-following-clinical-setbacks-in-pelacarsen-and-eplontersen-28bc1b

    EQUITY
    Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen
    Ionis Pharmaceuticals has faced substantial equity re-rating in 2026, falling more than 40% on the back of late-stage clinical trial disappointments and recurring operating losses. The pipeline setbacks have centered on lead programs pelacarsen and eplontersen, impacting near-term commercialization milestones. Despite the share price decline, sell-side consensus maintains an average target of $83.82, reflecting residual valuation attributed to Ionis's broad antisense oligonucleotide technology library and established partnerships with AstraZeneca, Roche, and Biogen.
    IONSAZNBIIB
    Impact
    63
    SEP 21
    SIG
    80%
    IONSAZNBIIB
    Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen
    Ionis Pharmaceuticals has faced substantial equity re-rating in 2026, falling more than 40% on the back of late-stage clinical trial disappointments and recurring operating losses. The pipeline setbacks have centered on lead programs pelacarsen and eplontersen, impacting near-term commercialization milestones. Despite the share price decline, sell-side consensus maintains an average target of $83.82, reflecting residual valuation attributed to Ionis's broad antisense oligonucleotide technology library and established partnerships with AstraZeneca, Roche, and Biogen.
    → Late-stage clinical trial failures in pelacarsen and eplontersen reduce projected licensing milestone revenues and royalty streams across partners AZN and BIIB, widening equity risk premia on developmental biotech platforms.
    Impact
    Ionis Pharmaceuticals has faced substantial equity re-rating in 2026, falling more than 40% on the back of late-stage clinical trial disappointments and recurring operating losses. The pipeline setbacks have centered on lead programs pelacarsen and eplontersen, impacting near-term commercialization milestones. Despite the share price decline, sell-side consensus maintains an average target of $83.82, reflecting residual valuation attributed to Ionis's broad antisense oligonucleotide technology library and established partnerships with AstraZeneca, Roche, and Biogen.
    Affected
    IONSAZNBIIB
    Transmission
    Late-stage clinical trial failures in pelacarsen and eplontersen reduce projected licensing milestone revenues and royalty streams across partners AZN and BIIB, widening equity risk premia on developmental biotech platforms.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSmilestone and commercial royalty impairment on clinical failuresDown1-3mSource confirms stock dropped >40% YTD following late-stage clinical trial failures in pelacarsen and eplontersen.
    AZNpartner pipeline asset risk adjustmentWatch1-4wSource identifies AstraZeneca as commercial development partner for Ionis pipeline assets.
    BIIBpartner neurology and antisense co-development exposureWatch1-4wSource lists Biogen among active development partners for Ionis ASO programs.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSDowndisagreed44.90 2026-09-21+1.89%+1.49%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month